CompoAtlas

Ashwagandha ULTRA STRENGTH 6,000 mg

Food supplement declared in France, decision dated 10 October 2026

Ashwagandha ULTRA STRENGTH 6,000 mg (Jamieson™) is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: Withania somnifera 300 mg per day, Withania somnifera 300 mg per day. None of the rules we check flags an issue with its declared composition.

Brand
Jamieson™
Food business operator placing the product on the market
Jamieson Health Products Netherlands B.V.
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Capsule
Daily dose
1 gélule
Directions for use
Adultes : Prendre 1 gélule par jour.
Intended populations
Men and women aged 18 and over
Not recommended (according to the manufacturer)
Adolescents (moins de 18 ans), Femmes allaitantes, Autre : Equilibre mental - Amélioration de la résistance de l'organisme au stress, Enfants (moins de 12 ans), Enfants en bas âge (1 à 3 ans), Femmes enceintes, Nourrissons (moins de 1 an), Problèmes cardiaques, Problèmes de foie, Sous traitement pour la thyroïde, Enfants (de moins de 6 ans), Enfants (de moins de 10 ans)
Objectives stated by the manufacturer (these are not authorised claims)
Mémoire, Autre : Equilibre mental - Amélioration de la résistance de l'organisme au stress, Humeur

Declaration 378139, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Withania somnifera (L.) DunalRacineExtrait sec hydroalcoolique300 mg
Withania somnifera (L.) DunalParties aériennesExtrait sec hydroalcoolique300 mg

Additives

E551, E470b, E460, E464, E341

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Has the product changed? Photograph the packaging.

Label warnings

Déconseillé aux femmes enceintes ou allaitantes, aux personnes de moins de 18 ans, aux personnes souffrant de troubles endocriniens (notamment de troubles thyroïdiens et d’hyperandrogénie), aux personnes souffrant de troubles cardiaques, lors de la conduite de véhicules ou de l’utilisation de machines et/ou en association avec des substances ayant un effet dépresseur sur le système nerveux central. Ne pas utiliser en cas de troubles hépatiques. Cessez l’utilisation et consultez un professionnel de santé si vous présentez des symptômes de troubles hépatiques tels que des douleurs abdominales, une jaunisse ou des symptômes similaires.

Regulatory points

None of the rules we check applies to the declared ingredients.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Withania somnifera (L.) Dunal
    Read the warning, when it applies and the studies cited

    ASHWAGANDHA - WITHANIA SOMNIFERA

    Route of administration: Oral

    Cautions and warnings

    Condition of application: General debility; Memory enhancement; Adaptogen; Restlessness/nervousness.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Upton 2000; McGuffin et al. 1997).

    Sources cited by Health Canada (3)
    • McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press, LLC; 1997.
    • Upton R, editor. American Herbal Pharmacopoeia and Therapeutic Compendium: Ashwagandha Root (Withania somnifera) - Standards of Analysis, Quality Control, and Therapeutics. Santa Cruz (CA): American Herbal Pharmacopoeia; 2000.
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze K, éditeurs. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13e édition. Washington (DC) : American Pharmaceutical Association; 2002.

    When using this product exercise caution if you drive or use machinery as you may experience drowsiness (Berardi et al. 2002).

    Sources cited by Health Canada (3)
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA and Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
    • McGuffin M, Hobbs C, Upton R, Goldberg A, éditeurs. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL) : CRC Press, LLC; 1997.
    • Upton R, éditeur. Ashwagandha Root, Withania somnifera Analytical, Quality Control, And Therapeutic Monograph. Santa Cruz (CA) : American Herbal Pharmacopoeia and Therapeutic Compendium; 2000.

    Health Canada monograph dated 28 February 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Brand : Jamieson™

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “Ashwagandha ULTRA STRENGTH 6,000 mg (Jamieson™): composition and regulation”, https://compoatlas.com/en/supplements/products/378139-ashwagandha-ultra-strength-6-000-mg, updated 15 November 2026.

Enter to analyse, Shift+Enter for a new line